Dr. Reddy's Laboratories announces the launch of Raloxifene HCl Tablets, USP in the U.S. Market
Hyderabad, India and Princeton, NJ, USA. 11 November 2016 - Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Raloxifene hydrochloride tablets in 60 mg, a therapeutic equivalent generic version of Evista® (raloxifene hydrochloride) tablets in the United States market, approved by the U.S. Food & Drug Administration (USFDA). The Evista® brand and generic had U.S. sales of approximately $265 million MAT for the most recent twelve months ending in September 2016 according to IMS Health*. Dr. Reddy’s Raloxifene tablets are available in 60 mg in bottle count sizes of 30, 100 and 1,000. Evista® is a registered trademark of Eli Lilly and Company. *IMS National Sales Perspective: Retail and Non-Retail MAT September 2016 RDY-1016-134
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
Raloxifene is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. It is used for prevention of osteoporosis in postmenopausal women. Raloxifene HCl
ReplyDelete